Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: influenza DNA vaccines - Inovio

Drug Profile

Research programme: influenza DNA vaccines - Inovio

Alternative Names: GLS-3700; H3HA DNA vaccine - Inovio; H3N2 influenza DNA vaccine - Inovio; H7N9 influenza DNA vaccine - Inovio; Influenza A virus H7N9 DNA vaccine - Inovio; Pandemic influenza DNA vaccine - Inovio; Prophylactic pre-pandemic influenza DNA vaccine cocktail (VGX-3500) - Inovio; Seasonal influenza DNA vaccine - Inovio; SynCon™ universal flu vaccine - Inovio; Universal Flu DNA Vaccine - Inovio; Universal Influenza DNA Vaccine - Inovio; VGX 3500; VGX-3500 (H5 + H1) DNA vaccine; VGX-3500X

Latest Information Update: 28 Oct 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Inovio Biomedical Corporation; VGX International
  • Developer Inovio Pharmaceuticals
  • Class Influenza A virus H1N1 vaccines; Influenza A virus H5N1 vaccines; Influenza A virus H7N9 vaccines; Influenza virus DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Influenza A virus H1N1 subtype; Influenza A virus H3N2 subtype; Influenza A virus H5N1 subtype; Influenza A virus H7N9 subtype; Influenza virus infections

Most Recent Events

  • 28 Oct 2022 No recent reports of development identified for preclinical development in Influenza-A virus H3N2 subtype(Prevention) in USA (Parenteral, Injection)
  • 28 Sep 2020 No recent reports of development identified for preclinical development in Influenza-A-virus-H1N1-subtype(Prevention) in USA (Parenteral, Injection)
  • 17 Sep 2018 Preclinical development is ongoing in Influenza-A-virus-H1N1-subtype (Prevention) in USA (Parenteral, Injection)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top